Business
Adial Pharmaceuticals Commends Congress on Introduction of Bipartisan Legislation Expanding Access to Emerging AUD Therapies for Veterans
H.R. 7091 Supports Development of Investigational Treatments for Alcohol Use Disorder and Aligns with Evolving Federal Recovery StandardsGLEN ALLEN, Va., March 24, 2026 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of treatments for addiction and related disorders, today commended members of the U.S. Congress for introducing H.R. 7091, the Expanding Veterans’ Access to Emerging Trea
About this update from Adial Pharmaceuticals, Inc
[{"type":"image","alt":"Adial Pharmaceuticals, Inc","displaySize":"","headline":null,"caption":"Adial Pharmaceuticals, Inc","className":"","disableSlideshowImg":false,"size":{"original":{"width":282,"height":123,"url":"https://media.zenfs.com/en/globenewswire.com/1a7a0a453f63a638e99b1c536ceba3a8"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/OS8RFd1l80uKUbwh6NVCzw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE4Mw--/https://media.zenfs.com/en/globenewswire.com/1a7a0a453f63a638e99b1c536ceba3a8","width":282,"height":123},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/OS8RFd1l80uKUbwh6NVCzw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE4Mw--/https://media.zenfs.com/en/globenewswire.com/1a7a0a453f63a638e99b1c536ceba3a8","width":282,"height":123}},"lazy":false},{"type":"text","content":"H.R. 7091 Supports Development of Investigational Treatments for Alcohol Use Disorder and Aligns with Evolving Federal Recovery Standards","length":137,"tagName":"p"},{"type":"text","content":"GLEN ALLEN, Va., March 24, 2026 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of treatments for addiction and related disorders, today commended members of the U.S. Congress for introducing H.R. 7091, the Expanding Veterans’ Access to Emerging Treatments Act, bipartisan legislation aimed at expanding research and development of emerging therapies for conditions affecting U.S. veterans, specifically including Alcohol Use Disorder (AUD).","length":559,"tagName":"p"},{"type":"text","content":"Alcohol Use Disorder remains a significant issue within the veteran population, with nearly 40% of veterans experiencing AUD at some point in their lives. Despite the prevalence and impact of the condition, existing Food & Drug Administration-approved treatment options are abstinence based, limiting therapeutic approaches for many patients.","length":346,"tagName":"p"},{"type":"text","content":"H.R. 7091 specifically includes AUD among the conditions eligible for expanded research and development efforts. The legislation supports investigational pharmaceutical therapies that meet the U.S. Government’s updated definition of recovery, which includes non-abstinence based treatment options. This definition reflects evolving federal policy recognizing harm reduction and reductions in heavy d...